Clinicopathological and prognostic significance of heat shock proteins in hepatocellular carcinoma: a systematic review and meta-analysis.
clinicopathological significance
heat shock proteins
hepatocellular carcinoma
meta-analysis
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
11
04
2023
accepted:
17
07
2023
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
Overexpression of heat shock proteins (HSPs) has been observed in a wide range of human tumors, and there is an increasing evidence demonstrated that HSPs play a key role in tumor progression. Several studies were conducted to explore the clinicopathological characteristics and prognostic value of HSPs in hepatocellular carcinoma (HCC), but the results remain controversial. To address this gap, we conducted a systematic review and meta-analysis. The eligible literature was obtained from PubMed, Cochrane library, Web of science, Embase, Chinese National Knowledge Infrastructure and Wan Fang databases. We used the odds ratio (OR) and hazard ratio (HR) as the suitable parameters to assess the clinicopathological features and prognostic value of HSPs in HCC patients. The meta-analysis results showed that HSPs expression was associated with overall survival (OS) of HCC patients (HR = 1.61, 95%CI = 1.22-2.13, Our meta-analysis confirms that HSPs expression is closely associated with a worse prognosis in HCC patients, and may be directly involved in tumor differentiation and distant metastasis. In addition, the subgroup analysis results demonstrate that the expression of HSP27 and HSP90α can be served as potential prognostic predictors of HCC.
Sections du résumé
Background
UNASSIGNED
Overexpression of heat shock proteins (HSPs) has been observed in a wide range of human tumors, and there is an increasing evidence demonstrated that HSPs play a key role in tumor progression. Several studies were conducted to explore the clinicopathological characteristics and prognostic value of HSPs in hepatocellular carcinoma (HCC), but the results remain controversial. To address this gap, we conducted a systematic review and meta-analysis.
Methods
UNASSIGNED
The eligible literature was obtained from PubMed, Cochrane library, Web of science, Embase, Chinese National Knowledge Infrastructure and Wan Fang databases. We used the odds ratio (OR) and hazard ratio (HR) as the suitable parameters to assess the clinicopathological features and prognostic value of HSPs in HCC patients.
Results
UNASSIGNED
The meta-analysis results showed that HSPs expression was associated with overall survival (OS) of HCC patients (HR = 1.61, 95%CI = 1.22-2.13,
Conclusions
UNASSIGNED
Our meta-analysis confirms that HSPs expression is closely associated with a worse prognosis in HCC patients, and may be directly involved in tumor differentiation and distant metastasis. In addition, the subgroup analysis results demonstrate that the expression of HSP27 and HSP90α can be served as potential prognostic predictors of HCC.
Identifiants
pubmed: 37601679
doi: 10.3389/fonc.2023.1169979
pmc: PMC10436519
doi:
Types de publication
Systematic Review
Langues
eng
Pagination
1169979Informations de copyright
Copyright © 2023 Xiang, Jiang, Chen, Liu and Li.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Onco Targets Ther. 2018 Jan 15;11:351-359
pubmed: 29391812
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Cells. 2020 Jun 01;9(6):
pubmed: 32492896
Cells. 2020 May 20;9(5):
pubmed: 32443761
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Cancer Lett. 2012 Apr 28;317(2):157-64
pubmed: 22115967
Mol Biol Cell. 2012 Feb;23(4):602-13
pubmed: 22190738
Hepatol Int. 2022 Oct;16(5):1208-1219
pubmed: 35972640
Gastroenterology. 2007 Jun;132(7):2557-76
pubmed: 17570226
N Engl J Med. 2011 Sep 22;365(12):1118-27
pubmed: 21992124
Cancer Biol Med. 2021 Mar 25;:
pubmed: 33764710
J Cell Physiol. 2020 Dec;235(12):9110-9120
pubmed: 32452023
Cells. 2019 Dec 24;9(1):
pubmed: 31878360
Int J Mol Med. 2016 Mar;37(3):825-35
pubmed: 26846697
Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):881-96
pubmed: 25260315
Curr Drug Targets. 2018;19(13):1478-1490
pubmed: 28831912
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Hepatobiliary Pancreat Sci. 2011 Jul;18(4):544-50
pubmed: 21234611
Trends Biochem Sci. 2006 Mar;31(3):164-72
pubmed: 16483782
Mol Cancer. 2017 Dec 20;16(1):178
pubmed: 29262861
Anticancer Res. 2016 Jul;36(7):3775-9
pubmed: 27354654
Hepatology. 2012 Oct;56(4):1371-9
pubmed: 22535689
EBioMedicine. 2017 Oct;24:56-63
pubmed: 28939487
Liver Int. 2004 Aug;24(4):316-21
pubmed: 15287854
Aliment Pharmacol Ther. 2020 Aug;52(4):701-709
pubmed: 32598091
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Genes Dis. 2020 Apr 07;7(3):328-335
pubmed: 32884987
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cell Physiol Biochem. 2017;42(6):2507-2522
pubmed: 28848092
Theranostics. 2016 Feb 17;6(4):558-70
pubmed: 26941848
J Hematol Oncol. 2019 Dec 9;12(1):133
pubmed: 31815633
JAMA Surg. 2017 Jan 1;152(1):55-64
pubmed: 27706479
Medicine (Baltimore). 2021 Jan 22;100(3):e24274
pubmed: 33546049
Cell Mol Life Sci. 2021 May;78(9):4069-4083
pubmed: 33544155
Cell Stress Chaperones. 2009 Jan;14(1):105-11
pubmed: 18663603
Am J Gastroenterol. 2006 Mar;101(3):524-32
pubmed: 16542289
Hum Pathol. 2019 Apr;86:193-202
pubmed: 30529751
Onco Targets Ther. 2018 Mar 07;11:1293-1303
pubmed: 29563808
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Korean Med Sci. 2005 Oct;20(5):829-34
pubmed: 16224158
Biology (Basel). 2021 Mar 22;10(3):
pubmed: 33810095
Contemp Oncol (Pozn). 2021;25(2):73-79
pubmed: 34667432
Clin J Oncol Nurs. 2008 Oct;12(5):759-66
pubmed: 18842532
Proteomics. 2006 Feb;6(3):1049-57
pubmed: 16400691
Oncotarget. 2017 Jul 5;8(33):54978-54992
pubmed: 28903396
Cell Stress Chaperones. 2005 Summer;10(2):86-103
pubmed: 16038406
Mol Aspects Med. 2008 Feb-Apr;29(1-2):130-43
pubmed: 18061252
Immunogenetics. 1990;32(4):242-51
pubmed: 1700760
Future Med Chem. 2012 May;4(7):927-35
pubmed: 22571616
Cancer. 2000 Jun 1;88(11):2464-70
pubmed: 10861421
Gut Liver. 2014 Jan;8(1):79-87
pubmed: 24516705
Oncotarget. 2014 May 15;5(9):2648-63
pubmed: 24798191
Heliyon. 2020 Sep 23;6(9):e05002
pubmed: 33005803